Abatacept Significantly Reduces Subclinical Inflammation During Treatment (6 Months), This Persists After Discontinuation (12 Months), Resulting in a Delay in the Clinical Development of RA in Patients at Risk of RA (The ARIAA Study)

Rech J, Kleyer A, Ostergaard M, Hagen M, Mendez LV, Tascilar K, Krönke G, Schönau V, Simon D, Kleinert S, Baraliakos X, Braun J, Hueber A, Fleck M, Rubbert-Roth A, Behrens F, Feuchtenberger M, Zaenker M, Voll R, Glaser C, Filkova M, Feist E, Burmester G, Karberg K, Strunk J, Canete J, Senolt L, Naredo E, Schett G (2022)

Publication Type: Conference contribution

Publication year: 2022

Journal

Arthritis and Rheumatology Wiley

Publisher: WILEY

City/Town: HOBOKEN

Pages Range: 1067-1069

Conference Proceedings Title: ARTHRITIS & RHEUMATOLOGY

Authors with CRIS profile

Hans Jürgen Rech Einrichtungen, die zum Universitätsklinikum Erlangen gehören Arnd Kleyer Department of Medicine 3 – Rheumatology and Immunology Melanie Hagen Department of Medicine 3 – Rheumatology and Immunology Koray Tascilar Department of Medicine 3 – Rheumatology and Immunology Gerhard Krönke Department of Medicine 3 – Rheumatology and Immunology David Simon Department of Medicine 3 – Rheumatology and Immunology Georg Schett Lehrstuhl für Innere Medizin III

Involved external institutions

Hospital Clínic de Barcelona ES Spain (ES) Charité - Universitätsmedizin Berlin DE Germany (DE) Klinikum Nürnberg DE Germany (DE) Asklepios Kliniken DE Germany (DE) Ruhr-Universität Bochum (RUB) DE Germany (DE) Goethe-Universität Frankfurt am Main DE Germany (DE) Universitätsklinikum Freiburg DE Germany (DE) Univerzita Karlova v Praze / Charles University in Prague CZ Czech Republic (CZ) HELIOS Kliniken DE Germany (DE) Kantonsspital St.Gallen CH Switzerland (CH) Krankenhaus Porz am Rhein DE Germany (DE) Rheumazentrum Ruhrgebiet DE Germany (DE) Immanuel Klinikum Bernau DE Germany (DE) Hospital General Universitario Gregorio Marañón ES Spain (ES)

How to cite

APA:

Rech, J., Kleyer, A., Ostergaard, M., Hagen, M., Mendez, L.V., Tascilar, K.,... Schett, G. (2022). Abatacept Significantly Reduces Subclinical Inflammation During Treatment (6 Months), This Persists After Discontinuation (12 Months), Resulting in a Delay in the Clinical Development of RA in Patients at Risk of RA (The ARIAA Study). In ARTHRITIS & RHEUMATOLOGY (pp. 1067-1069). HOBOKEN: WILEY.

MLA:

Rech, Jürgen, et al. "Abatacept Significantly Reduces Subclinical Inflammation During Treatment (6 Months), This Persists After Discontinuation (12 Months), Resulting in a Delay in the Clinical Development of RA in Patients at Risk of RA (The ARIAA Study)." Proceedings of the ARTHRITIS & RHEUMATOLOGY HOBOKEN: WILEY, 2022. 1067-1069.

BibTeX: Download